Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P7PY
|
|||
| Drug Name |
Cirmtuzumab
|
|||
| Synonyms |
UC-961
Click to Show/Hide
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [1] | |
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1/2 | [2] | ||
| Company |
Oncternal Therapeutics San Diego, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neurotrophic tyrosine kinase ROR1 (ROR1) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Wnt signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04501939) Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (Venetoclax). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.